A randomised, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib.

This study will evaluate the effectiveness, safety and tolerability of a drug, remibrutinib, as a treatment for patients with relapsing multiple sclerosis.